John Maraganore - Dec 21, 2021 Form 4 Insider Report for ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Signature
By: /s/ Mary Beth DeLena, Attorney-in-Fact For: John M. Maraganore
Stock symbol
ALNY
Transactions as of
Dec 21, 2021
Transactions value $
-$1,254,077
Form type
4
Date filed
12/23/2021, 04:00 PM
Previous filing
Dec 14, 2021
Next filing
Jan 19, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALNY Common Stock Award $0 +14.2K +6.44% $0.00 234K Dec 21, 2021 Direct F1
transaction ALNY Common Stock Tax liability -$1.19M -6.32K -2.7% $189.13 228K Dec 22, 2021 Direct F2
transaction ALNY Common Stock Tax liability -$381 -2 0% $190.50 228K Dec 22, 2021 Direct F2
transaction ALNY Common Stock Tax liability -$59.3K -319 -0.14% $186.02 228K Dec 22, 2021 Direct F2
holding ALNY Common Stock 3.13K Dec 21, 2021 by Managed Account F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 28, 2019, the reporting person was granted performance-based restricted stock units (PSU) in connection with the 2018 year-end compensation review. One third of the PSU award vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the final performance criterion was met and the final one-third of the PSU award vested as of December 21, 2021.
F2 Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event.
F3 Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.